194 related articles for article (PubMed ID: 33381588)
1. Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis.
Li J; Yin J; Zhong J; Yang Z; Tang A; Li S
Biomed Res Int; 2020; 2020():8828579. PubMed ID: 33381588
[TBL] [Abstract][Full Text] [Related]
2. Expression of MCSP and PRAME in conjunctival melanoma.
Westekemper H; Karimi S; Süsskind D; Anastassiou G; Freistühler M; Meller D; Zeschnigk M; Steuhl KP; Bornfeld N; Schmid KW; Grabellus F
Br J Ophthalmol; 2010 Oct; 94(10):1322-7. PubMed ID: 20805128
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis.
Jiao R; Jiang W; Wei X; Zhang M; Zhao S; Huang G
BMC Cancer; 2020 Jul; 20(1):662. PubMed ID: 32677912
[TBL] [Abstract][Full Text] [Related]
5. The effect of preferentially expressed antigen in melanoma (PRAME) expression status on survival in stage II and stage III colon cancer.
Ogul A; Paydas S; Doran F; Erdogan KE; Tohumcuoglu M; Buyuksimsek M; Mirili C; Yetisir AE
J BUON; 2021; 26(3):992-1001. PubMed ID: 34268964
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
[TBL] [Abstract][Full Text] [Related]
8.
Baba H; Kanda M; Sawaki K; Shimizu D; Umeda S; Koike M; Kodera Y; Fujii T
Anticancer Res; 2019 Nov; 39(11):5943-5951. PubMed ID: 31704819
[TBL] [Abstract][Full Text] [Related]
9. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of LINC00460 overexpression in solid tumours: a meta-analysis.
Dai C; Zhang Y; Ni H; Kuang Y; Xu Z
Postgrad Med J; 2020 May; 96(1135):286-295. PubMed ID: 32054779
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
13. PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer.
Baba H; Kanda M; Sawaki K; Umeda S; Miwa T; Shimizu D; Tanaka C; Kobayashi D; Fujiwara M; Kodera Y; Fujii T
Ann Surg Oncol; 2020 Jun; 27(6):2071-2080. PubMed ID: 31659640
[TBL] [Abstract][Full Text] [Related]
14. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
[TBL] [Abstract][Full Text] [Related]
15. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
16. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
Qin Y; Lu J; Bao L; Zhu H; Li J; Li L; Lai Y; Shi H; Wang Y; Liu Y; Jiang B; Huang X
Chin Med J (Engl); 2014; 127(9):1666-71. PubMed ID: 24791872
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of long non-coding RNA UCA1 in human solid tumors.
Liu FT; Zhu PQ; Luo HL; Zhang Y; Qiu C
Oncotarget; 2016 Sep; 7(36):57991-58000. PubMed ID: 27517147
[TBL] [Abstract][Full Text] [Related]
20. PRAME expression in 155 cases of metastatic melanoma.
Gradecki SE; Slingluff CL; Gru AA
J Cutan Pathol; 2021 Apr; 48(4):479-485. PubMed ID: 32939793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
